

An Evaluation of Inferential Procedures for Adaptive Clinical Trial Designs with Pre-specified Rules for Modifying the Sample Size

Gregory P. Levin, Sarah C. Emerson, & Scott S. Emerson

Cesar Torres

June 3, 2014

Overview

- ▶ Review
- ▶ Distribution of sampling density
- ▶ Simulation results
- ▶ Concerns (Criticisms)
- ▶ More simulation results

Review: Motivating Example

Suppose researchers want to cure [insert type of cancer here], because said cancer is bad.


- ▶ Two-arm clinical trial
- ▶ Can observe X_{plac_i} 's and X_{treat_i} 's
 - ▶ $X_{\text{plac}_i} \stackrel{\text{iid}}{\sim} \mathcal{N}(\mu_{\text{plac}}, \sigma^2)$
 - ▶ $X_{\text{treat}_i} \stackrel{\text{iid}}{\sim} \mathcal{N}(\mu_{\text{treat}}, \sigma^2)$
 - ▶ $\sigma^2 > 0$ known
- ▶ Defining $\theta := \mu_{\text{treat}} - \mu_{\text{plac}}$, interested in testing $H_0 : \theta \leq 0$ vs. $H_1 : \theta > 0$
- ▶ Issue of concern: lots of treatments to evaluate

Review: Clinical Trial Designs

- ▶ “Well-understood” designs
 - ▶ Fixed design
 - ▶ Group sequential design
- ▶ “Less well-understood” designs
 - ▶ Adaptive design
 - ▶ The focus of this paper


Review: Fixed Design

Example of Clinical Trial with Fixed Design




Review: Fixed Design

Example of Clinical Trial with Fixed Design




Review: Fixed Design

Example of Clinical Trial with Fixed Design




Review: Group Sequential Design

Example of Clinical Trial with Group Sequential Design




Review: Group Sequential Design

Example of Clinical Trial with Group Sequential Design




Review: Group Sequential Design

Example of Clinical Trial with Group Sequential Design




Review: Group Sequential Design

Example of Clinical Trial with Group Sequential Design




Review: Group Sequential Design

Example of Clinical Trial with Group Sequential Design




Review: Group Sequential Design

Example of Clinical Trial with Group Sequential Design




Review: Group Sequential Design

Example of Clinical Trial with Group Sequential Design




Review: Adaptive Design

Simple Example of Clinical Trial with Adaptive Design




Review: Adaptive Design

Simple Example of Clinical Trial with Adaptive Design




Review: Adaptive Design

Simple Example of Clinical Trial with Adaptive Design



Review: Adaptive Design

Simple Example of Clinical Trial with Adaptive Design



Review: Inference when using GS or Adaptive Designs

- ▶ Neyman-Pearson lemma, Karlin-Rubin theorem not applicable
 - ▶ Likelihood ratio not monotone non-decreasing when using group-sequential-like designs
- ▶ Need some way (some ordering) to determine what are “extreme” observations under the null hypothesis

Review: Considered Orderings

- ▶ Sample mean
- ▶ Signed LR: If \forall fixed θ^* ,

$$\text{sign}(\hat{\theta}_{(1)} - \theta^*) \frac{f(\text{outcome 1} | \theta = \hat{\theta}_{(1)})}{f(\text{outcome 1} | \theta = \theta^*)} > \text{sign}(\hat{\theta}_{(2)} - \theta^*) \frac{f(\text{outcome 2} | \theta = \hat{\theta}_{(2)})}{f(\text{outcome 2} | \theta = \theta^*)},$$

then outcome 1 ordered higher than outcome 2, with $\hat{\theta}_{(i)}$ the sample mean from outcome i

- ▶ Conditional Error Ordering: Outcomes ordered according to the stage-wise p-value of “backward image”

Review: Point Estimates

Three point estimates considered

- ▶ Sample mean (MLE) $\hat{\theta}$
- ▶ Bias adjusted mean (BAM) $\hat{\eta}$: the value θ for which $\hat{\theta}$ is the mean
- ▶ Median-unbiased estimate (MUE) $\hat{\zeta}$: the value θ for which $\hat{\theta}$ is the median

Distribution of Sampling Density

Law of Total Probability:

$$\begin{aligned}F_{\hat{\theta}|\theta}(x) &= P_{\theta}(\hat{\theta} \leq x) \\&= \sum_{i=0}^n P_{\theta}(\hat{\theta} \leq x | C_i) P_{\theta}(C_i) \\&= \sum_{i=0}^n F_{\hat{\theta}|\theta, C_i}(x) P_{\theta}(C_i).\end{aligned}$$

Taking derivatives:

$$\begin{aligned}f_{\hat{\theta}|\theta}(x) &= \frac{d}{dx} F_{\hat{\theta}|\theta}(x) \\&= \frac{d}{dx} \sum_{i=0}^n F_{\hat{\theta}|\theta, C_i}(x) P_{\theta}(C_i) \\&= \sum_{i=0}^n \frac{d}{dx} F_{\hat{\theta}|\theta, C_i}(x) P_{\theta}(C_i) \\&= \sum_{i=0}^n f_{\hat{\theta}|\theta, C_i}(x) P_{\theta}(C_i).\end{aligned}$$


Distribution of Sampling Density

\mathcal{C}_0 : the stopping region.

$$\begin{aligned} F_{\hat{\theta}|\theta, \mathcal{C}_0}(x) &= P_{\theta}(\hat{\theta} \leq x | \mathcal{C}_0) \\ &= P_{\theta}(\hat{\theta} \leq x | \hat{\theta}_1 \notin (a_1, d_1)) \\ &= \frac{P_{\theta}(\hat{\theta} \leq x, \hat{\theta}_1 \notin (a_1, d_1))}{P_{\theta}(\hat{\theta}_1 \notin (a_1, d_1))} \\ &= \frac{F_{\hat{\theta}_1|\theta}(x) \times 1_{\{\hat{\theta}_1 \notin (a_1, d_1)\}}}{P_{\theta}(\hat{\theta}_1 \notin (a_1, d_1))} \end{aligned}$$

Review: Adaptive Design

Simple Example of Clinical Trial with Adaptive Design



Distribution of Sampling Density

Taking derivatives once more:

$$\begin{aligned} f_{\hat{\theta}|\theta, \mathcal{C}_0}(x) &= \frac{d}{dx} F_{\hat{\theta}|\theta, \mathcal{C}_0}(x) \\ &= \frac{f_{\hat{\theta}_1|\theta}(x) \times 1_{\{\hat{\theta}_1 \notin (a_1, d_1)\}}}{P_{\theta}(\hat{\theta}_1 \notin (a_1, d_1))}. \end{aligned}$$

Distribution of Sampling Density

$\mathcal{C}_i, i \geq 1$: a continuation region.

- ▶ m = sample size at interim analysis
- ▶ $N = m + n$ = sample size at final analysis
- ▶ $\hat{\theta} = \frac{m}{N} \times \hat{\theta}_1 + \frac{n}{N} \times \hat{\theta}_2$

Distribution of Sampling Density

$\mathcal{C}_i, i \geq 1$: a continuation region.

$$\begin{aligned}F_{\hat{\theta}|\hat{\theta}_1=x}(z) &= P_{\theta}\left(\hat{\theta} \leq z|\hat{\theta}_1 = x\right) \\&= P_{\theta}\left(\frac{m}{N} \times \hat{\theta}_1 + \frac{n}{N} \times \hat{\theta}_2 \leq z|\hat{\theta}_1 = x\right) \\&= (\text{some algebra}) \\&= F_{\hat{\theta}_2|\theta}\left(\frac{N}{n} \left(z - \frac{mx}{N}\right)\right)\end{aligned}$$

Derivative:

$$f_{\hat{\theta}|\hat{\theta}_1=x}(z) = f_{\hat{\theta}_2|\theta}\left(\frac{N}{n} \left(z - \frac{mx}{N}\right)\right) \frac{N}{n}$$

Distribution of Sampling Density

$\mathcal{C}_i, i \geq 1$: a continuation region. Convolution:

$$f_{\hat{\theta}|\mathcal{C}_i}(z) = \int_{-\infty}^{\infty} f_{\hat{\theta}|\hat{\theta}_1}(z)f_{\hat{\theta}_1}(x)dx$$

- R can compute this numerically.

Simulation Results

Settings:

- ▶ Recalling that $\theta := \mu_{treat} - \mu_{plac}$, interested in testing $H_0 : \theta \leq 0$ vs. $H_1 : \theta > 0$
- ▶ Assumed: $\sigma^2 = 0.5$
- ▶ Desired: Level $\alpha = 0.025$ at $\theta = 0$, power of 0.9 at $\theta = 1$
- ▶ Continuation region from original GS design divided into 10 equally sized continuation regions
- ▶ Adaptive rule: Final sample size $N^*(t) = 2.02N - 1.627(t - 1.96)$, with t the midpoint of the new continuation region.
- ▶ Standard boundaries derived similarly to those in GS design


Simulation Results

Procedure:

- ▶ Through grid search, get boundaries and sample sizes needed to achieve desired size and power
 - ▶ Computationally demanding
- ▶ Run clinical trial (or simulate data)
 - ▶ Computationally easy
- ▶ Draw inference from observed data
 - ▶ Computationally **intense**


Simulation Results

Scenario 1: Distribution assumptions hold



Simulation Results

Scenario 1: Distribution assumptions hold




Concern

Distribution Assumptions

- ▶ Known variance
- ▶ Normality


Simulation Results

Scenario 2: Normality holds, but true $\sigma^2 = 1$




Simulation Results

Scenario 2: Normality holds, but true $\sigma^2 = 1$




Simulation Results

Scenario 3: Data exponentially distributed, appropriately scaled and shifted so that $\sigma^2 = 0.5$ and $\theta \in (0, 2)$



Simulation Results

Scenario 3: Data exponentially distributed, appropriately scaled and shifted so that $\sigma^2 = 0.5$



Additional Concern

Knowledge of the final sample size is potentially unblinding.

- ▶ Same could be said of group sequential design, but group sequential design is widely accepted
 - ▶ Not a great answer, but it's something
- ▶ No clear way to quantify effects of such an unblinding

Summary

- ▶ Whether or not adaptive designs are a good idea, they are implemented to find cures for things such as [insert type of cancer here], so their properties need to be understood
- ▶ Under sample mean ordering and either type of boundary design, all 3 estimators do reasonably well, and confidence intervals do okay when θ is close to 0
- ▶ Inference not necessarily robust to violations of distribution assumptions

Questions?